UpdatesPress Release
Marksans Pharma delivered record quarterly profitability with PAT up 174% to ₹159 Cr and EBITDA rising 113% to ₹213 Cr.
Marksans Pharma LimitedMARKSANS · Filed with the exchange
Cash crossed ₹1,000 Cr.
UK & Europe revenue hit a high of ₹356 Cr, with acquisitions QliniQ and ABCnow bolstering European expansion.
No comments yet. Be the first.